Over the past decade, the treatment paradigm of advanced non-small cell lung cancer (NSCLC) has shifted with the introduction of therapies targeting immune checkpoint molecules, including programmed cell death protein 1 (PD-1) and its ligand (PD-L1). Here, PDCD1 is linked to non-small cell lung carcinoma.